Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Reform and the Changing Dynamics Between Payers and Drug Makers

This article was originally published in RPM Report

Executive Summary

Why drug makers should pay close attention to the pressures bearing down on payers.

You may also be interested in...



When Interests Align: Medication Adherence

When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.

Health Care Reform and the Biopharma Sector: A Complete Tactical Victory

The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?

Individualized Health Plans - The Bite of Demand-Side Discipline

Since the end of World War II, the employer-based health plan has been part of the social compact for many Americans. While Senator Barack Obama’s proposal for expanded coverage is greeted enthusiastically by those who favor change, Senator John McCain’s proposal offers the boldest departure from business as usual.

Topics

Latest News
UsernamePublicRestriction

Register

PS080758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel